What is Plasticell?
Founded in 2002, Plasticell specializes in the precise manipulation of stem cells and differentiated cell types. The company distinguishes itself through its award-winning combinatorial screening technology, which accelerates the discovery and development of novel regenerative therapies. By systematically exploring vast experimental spaces, Plasticell provides a robust framework for identifying optimal cell culture conditions, positioning itself as a critical player in the UK life sciences ecosystem. Its operational headquarters in Hertfordshire serves as a hub for high-throughput research and development, bridging the gap between academic discovery and clinical application.
How much funding has Plasticell raised?
Plasticell has raised a total of $2.7M across 2 funding rounds:
Other Financing Round
$774K
Private Equity
$1.9M
Other Financing Round (2007): $774K with participation from Innovate UK and Department of Trade & Industry
Private Equity (2021): $1.9M, investors not publicly disclosed
Key Investors in Plasticell
Innovate UK
Innovate UK is a government-backed innovation agency that provides critical funding and support to high-potential research and development projects within the United Kingdom.
Department of Trade & Industry
A former UK government department that historically provided foundational support and strategic oversight for industrial and technological development initiatives.
Undisclosed Investor
An undisclosed institutional investor participating in the most recent private equity round to support the company's enterprise-level scaling objectives.
What's next for Plasticell?
Following the recent strategic financing, Plasticell is well-positioned to scale its therapeutic pipeline and expand its intellectual property portfolio. The infusion of capital is expected to facilitate the transition of its lead candidates into advanced clinical trials, while simultaneously enhancing the throughput of its screening platforms. As the company matures, the focus will likely shift toward strategic partnerships with global pharmaceutical entities to validate its cell-based therapies at scale. This phase of growth underscores the company's commitment to addressing unmet medical needs through rigorous, data-driven innovation in the regenerative medicine space.
See full Plasticell company page
